For the year ending 2025-12-31, ISRG had $1,345,000K increase in cash & cash equivalents over the period. $2,490,700K in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net income | 2,876,600 | 2,337,500 | 1,817,300 | 1,344,400 |
| Depreciation and loss on disposal of property, plant, and equipment, net | 614,700 | 445,300 | 401,600 | 338,000 |
| Amortization of intangible assets | - | 16,700 | 20,200 | 27,800 |
| Amortization of intangible and other assets | 62,400 | - | - | - |
| Gain on sale of business | 1,000 | 1,100 | 0 | 3,800 |
| (gain) loss on investments and (accretion) amortization of investment discounts and premiums, net | 57,200 | 43,300 | -7,300 | -49,000 |
| Deferred income taxes | -19,100 | 135,300 | 280,800 | 185,300 |
| Share-based compensation expense | 788,200 | 676,800 | 592,800 | 513,200 |
| Amortization of contract acquisition assets | - | 37,700 | 33,000 | 26,600 |
| Accounts receivable | 301,700 | 95,900 | 186,300 | 159,300 |
| Inventory | 1,063,400 | 830,000 | 712,500 | 546,600 |
| Prepaids and other assets | 187,100 | 231,800 | -24,200 | 129,200 |
| Accounts payable | 57,900 | -400 | 41,700 | 21,300 |
| Accrued compensation and employee benefits | 112,700 | 99,300 | 34,800 | 51,500 |
| Deferred revenue | 75,200 | 31,200 | 53,400 | 21,500 |
| Other liabilities | 34,100 | 108,300 | -32,900 | 121,700 |
| Net cash provided by operating activities | 3,030,500 | 2,415,000 | 1,813,800 | 1,490,800 |
| Purchases of investments | 1,215,900 | 5,139,600 | 2,207,400 | 1,399,500 |
| Proceeds from sales of investments | 259,900 | 100,200 | 230,300 | 61,100 |
| Proceeds from maturities of investments | 2,175,500 | 2,878,800 | 2,690,100 | 3,254,400 |
| Purchases of property, plant, and equipment | 539,800 | 1,111,200 | 1,064,200 | 532,400 |
| Acquisition of businesses, net of cash, and intellectual property and other investing activities | 13,900 | 1,000 | 8,900 | 12,800 |
| Net cash provided by (used in) investing activities | 665,800 | -3,272,800 | -360,100 | 1,370,800 |
| Proceeds from issuance of common stock relating to employee stock plans | 350,300 | 429,400 | 296,300 | 233,800 |
| Taxes paid related to net share settlement of equity awards | 419,100 | 270,000 | 164,700 | 194,200 |
| Repurchases of common stock | 2,295,300 | 0 | 416,300 | 2,607,400 |
| Cash dividends paid by joint venture to noncontrolling interest | 0 | 8,000 | - | - |
| Payment of deferred purchase consideration | 0 | 500 | 2,900 | 4,500 |
| Net cash provided by (used in) financing activities | -2,364,100 | 150,900 | -287,600 | -2,572,300 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 12,800 | -800 | 3,300 | 5,400 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 1,345,000 | -707,700 | 1,169,400 | 294,700 |
| Cash and cash equivalents at beginning of period | 2,062,400 | 2,770,100 | 1,600,700 | 1,306,000 |
| Cash and cash equivalents at end of period | 3,407,400 | 2,062,400 | 2,770,100 | 1,600,700 |
INTUITIVE SURGICAL INC (ISRG)
INTUITIVE SURGICAL INC (ISRG)